November 2007
Worldwide Biotech;Nov2007, Vol. 19 Issue 11, p3
Trade Publication
The article reports that the State Food and Drug Administration of the People's Republic of China (SFDA) has granted Immtech Pharmaceutical Incorporated's application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the company's oral drug candidate for the treatment of Pneumocystis pneumonia (PCP). The drug is among the first to be considered for Fast Track Status under a more stringent SFDA rules introduced in China, according to the article.


Related Articles

  • Par Pharmaceutical Gains Rights To Phase III Drug From Immtech. Shrine, Jim // BioWorld Today;6/13/2007, Vol. 18 Issue 114, p1 

    The article reports that Par Pharmaceutical Cos. Inc. acquired exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in acquired immune deficiency syndrome (AIDS) patients. The goal of the Phase III study is to demonstrate...

  • Par Buys Rights To Phase III Drug From Immtech.  // Bioworld Week;6/18/2007, Vol. 15 Issue 25, p3 

    The article reports that Par Pharmaceutical Cos. Inc. has received exclusive rights to a Phase III oral drug pafuramidine maleate (DB289) from Immtech Pharmaceuticals Inc. in the U.S. The oral drug is for treating pneumocystis pneumonia in patients with acquired immune deficiency syndrome...

  • Everolimus.  // Reactions Weekly;9/7/2013, Issue 1468, p20 

    The article presents a case study of a 66-year-old man who developed pneumocystis pneumonia while being treated with everolimus.

  • Clinic Roundup.  // BioWorld Today;12/29/2010, Vol. 21 Issue 250, p5 

    The article reports that the China State Food and Drug Administration has approved an application by Sinovac Biotech Ltd. to commence clinical trials for its inactivated EV71 vaccine against hand, foot and mouth disease.

  • LESS FREQUENT TMP-SMX IS EFFECTIVE.  // AIDS Patient Care & STDs;Feb2000, Vol. 14 Issue 2, p104 

    Reports on research findings at Harlem Hospital in New York City that the frequency of dosing of TMP-SMX for prophylaxis of pneumocystis carinii pneumonia (PCP).

  • Excess Prevalence of Pneumocystis carinii Pneumonia in Patients Treated for Lymphoma with Combination Chemotherapy. Browne, Marcia J.; Hubbard, Susan M.; Longo, Dan L.; Fisher, Richard; Wesley, Robert; Ihde, Daniel C.; Young, Robert C.; Pizzo, Philip A. // Annals of Internal Medicine;Mar1986, Vol. 104 Issue 3, p338 

    Provides information on the excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Occurrence of Pneumocytis carinii pneumonia; Cases of pulmonary toxicity and Pneumocystis carinii pneumonia in patients with non-Hodgkin's lymphoma...

  • Immunosuppressants.  // Reactions Weekly;8/7/2010, Issue 1313, p25 

    The article describes ten case reports of patients who manifested with Pneumocystis carinii pneumonia associated with the use of prednisolone and in some cases, other immunosuppressants, referencing a study published in the January 2010 issue of the journal "Respirology."

  • Tacrolimus/mercaptopurine.  // Reactions Weekly;12/11/2010, Issue 1331, p31 

    The article describes the cases of two men in their 70s who developed Pneumocystis carinii pneumonia during treatment with tacrolimus and mercaptopurine for steroid-refractory ulcerative colitis (UC).

  • Dapsone.  // Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p16 

    The article presents a case study of a patient with acute generalised exanthematous pustulosis due to pneumocystis carinii pneumonia prophylaxis using dapsone.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics